Cite
Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir Therapy
MLA
Mark S. Sulkowski, et al. “Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir Therapy.” Gastroenterology, vol. 157, Dec. 2019, p. 1506–1517.e1. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....d8842c85f82ef84ca35e67ee3c1e94c9&authtype=sso&custid=ns315887.
APA
Mark S. Sulkowski, Mitchell L. Shiffman, Monika Vainorius, Joy Peter, Ira M. Jacobson, Lois Larsen, Larry Michael, Ira Willner, Anna S. Lok, Wenjing Lu, Gary P. Wang, Michael W. Fried, Giuseppe Morelli, Federico Hinestrosa, K. Rajender Reddy, David R. Nelson, Mohamed Hassan, Jens Kort, & Brian L. Pearlman. (2019). Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir Therapy. Gastroenterology, 157, 1506–1517.e1.
Chicago
Mark S. Sulkowski, Mitchell L. Shiffman, Monika Vainorius, Joy Peter, Ira M. Jacobson, Lois Larsen, Larry Michael, et al. 2019. “Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir Therapy.” Gastroenterology 157 (December): 1506–1517.e1. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....d8842c85f82ef84ca35e67ee3c1e94c9&authtype=sso&custid=ns315887.